Nuvalent Stock Today
| NUVL Stock | USD 77.01 2.53 3.40% |
PerformanceVery Weak
| Odds Of DistressLow
|
Nuvalent is selling for 77.01 as of the 16th of March 2025. This is a 3.40 percent increase since the beginning of the trading day. The stock's lowest day price was 76.0. Nuvalent has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Nuvalent Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 66.16 M outstanding shares of which 5.47 M shares are now shorted by private and institutional investors with about 13.8 trading days to cover. More on Nuvalent
Moving against Nuvalent Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nuvalent Stock Highlights
| President CEO | James Porter |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Nuvalent (NUVL) is traded on NASDAQ Exchange in USA. It is located in One Broadway, Cambridge, MA, United States, 02142 and employs 142 people. Nuvalent is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.51 B. Nuvalent conducts business under Biotechnology sector and is part of Health Care industry. The entity has 66.16 M outstanding shares of which 5.47 M shares are now shorted by private and institutional investors with about 13.8 trading days to cover.
Nuvalent currently holds about 256.96 M in cash with (185.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.31.
Check Nuvalent Probability Of Bankruptcy
Ownership AllocationThe majority of Nuvalent outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nuvalent to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nuvalent. Please pay attention to any change in the institutional holdings of Nuvalent as this could imply that something significant has changed or is about to change at the company.
Check Nuvalent Ownership Details
Nuvalent Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Nuvalent market risk premium is the additional return an investor will receive from holding Nuvalent long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | 0.1556 | |||
| Treynor Ratio | (1.38) |
Nuvalent Stock Against Markets
Nuvalent Corporate Management
| Darlene Noci | Chief Officer | Profile | |
| Matthew MBA | Senior Resources | Profile | |
| Perrin BS | Senior Strategy | Profile | |
| Prof Shair | Head Founder | Profile | |
| John Soglia | Senior Development | Profile | |
| Christopher MD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.